Strateos’ SVP of Strategy and Operations, Daniel Sipes, will be giving a talk during SLAS 2022 on February 7th at 4:30pm EST, discussing the challenges associated with the design, make, test and analyze (DMTA) cycle in small molecule drug discovery workflows where medicinal chemistry plays a key role. Progress from target ID through to IND submission in conventional workflows can take upwards of 6+ years, where success hinges on iterative cycles of DMTA. However, fractured workflows, operational bottlenecks and non-standardized analog data capture has resulted in high cost and slow cycle times that cannot support the urgent and growing demand for new drug discoveries.

Daniel will discuss key learnings and results of automating the DMTA cycle after over a year operating in production mode, including the reduction of researchers’ hands-on time by 90%, ability to screen 1M+ molecules in as little as two weeks to identify lead scaffolds, and automated reproducible synthesis of compounds followed by downstream cell-based and biochemical assays such as cAMP, kinase, and label-free mass spec assays in as little as 3-5 days.